WORCESTER, Mass., May 19, 2020 – Kelleher & Sadowsky Associates, Inc., a commercial real estate firm serving Worcester and Central Massachusetts, announced today the $1.5 million sale of a seven acre parcel of land at The Reactory on behalf of Worcester Business Development Corporation (WBDC) to WuXi Biologics (WuXi), a global contract development manufacturer of biological products on behalf of biotechnology and pharmaceutical companies. The Reactory is a 46-acre site that was purchased by the WBDC in 2017 from the Massachusetts Division of Capital Asset Management and Maintenance. The master planned biomanufacturing campus provides opportunity for up to 470,000 square feet of development with eight shovel-ready pads
WuXi Biologics, a global company with leading open-access biologics technology platforms, empowers biopharma organizations to discover, develop and manufacture drug products and vaccines. The approximately 110,000-square-foot, two-story facility will boast a total bioreactor capacity of 4,500 liters. Due to be operational in 2022, the new biomanufacturing facility will create 150 new jobs.
Representing WBDC, the seller of the property, was James G. Umphrey and Drew C. Higgins of Kelleher & Sadowsky. Representing WuXi, the buyer of the property, was Brian Cohen of CBRE-Boston.
According to Craig Blais, the president and CEO of the WBDC, research showed a strong need in the region for dedicated biomanufacturing space to meet the growing demand for genetically personalized medicine and the development of rare-disease treatments. “WuXi’s decision to locate their first US biomanufacturing facility in Worcester at The Reactory confirms the value of Worcester’s strong life sciences ecosystem and we expect other biotech manufacturers will soon follow their lead.”